AU2005217596B2 - Anti-ABeta antibody - Google Patents

Anti-ABeta antibody Download PDF

Info

Publication number
AU2005217596B2
AU2005217596B2 AU2005217596A AU2005217596A AU2005217596B2 AU 2005217596 B2 AU2005217596 B2 AU 2005217596B2 AU 2005217596 A AU2005217596 A AU 2005217596A AU 2005217596 A AU2005217596 A AU 2005217596A AU 2005217596 B2 AU2005217596 B2 AU 2005217596B2
Authority
AU
Australia
Prior art keywords
antibody
peptide
cells
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005217596A
Other languages
English (en)
Other versions
AU2005217596A1 (en
Inventor
Ronald Bradley Demattos
Uma Kuchibhotla
Don B. Mcclure
Hsiu-Chiung Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2005217596A1 publication Critical patent/AU2005217596A1/en
Application granted granted Critical
Publication of AU2005217596B2 publication Critical patent/AU2005217596B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AU2005217596A 2004-02-23 2005-02-17 Anti-ABeta antibody Ceased AU2005217596B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54676404P 2004-02-23 2004-02-23
US60/546,764 2004-02-23
PCT/US2005/005198 WO2005082939A2 (en) 2004-02-23 2005-02-17 Anti-abeta antibody

Publications (2)

Publication Number Publication Date
AU2005217596A1 AU2005217596A1 (en) 2005-09-09
AU2005217596B2 true AU2005217596B2 (en) 2012-01-19

Family

ID=34910810

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005217596A Ceased AU2005217596B2 (en) 2004-02-23 2005-02-17 Anti-ABeta antibody

Country Status (20)

Country Link
US (1) US20070190046A1 (https=)
EP (1) EP1720909B1 (https=)
JP (1) JP4851348B2 (https=)
KR (2) KR100889430B1 (https=)
CN (1) CN1922209B (https=)
AT (1) ATE534667T1 (https=)
AU (1) AU2005217596B2 (https=)
BR (1) BRPI0507856A (https=)
CA (1) CA2556436C (https=)
CY (1) CY1112162T1 (https=)
DK (1) DK1720909T3 (https=)
EA (1) EA009872B1 (https=)
ES (1) ES2375627T3 (https=)
IL (1) IL177611A (https=)
NO (1) NO20064239L (https=)
PL (1) PL1720909T3 (https=)
PT (1) PT1720909E (https=)
SI (1) SI1720909T1 (https=)
UA (1) UA93181C2 (https=)
WO (1) WO2005082939A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
EP1959996A2 (en) 2005-12-12 2008-08-27 AC Immune S.A. Monoclonal antibody
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
TW200844110A (en) 2007-01-11 2008-11-16 Univ Marburg Philipps Diagnosis and treatment of alzheimer's disease and other neurodementing diseases
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
BRPI0818623A2 (pt) * 2007-10-05 2017-05-23 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
AU2009319864A1 (en) 2008-11-25 2011-07-14 Biogen Idec Ma Inc. Use of DR6 and P75 antagonists to promote survival of cells of the nervous system
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
US20110110942A1 (en) 2009-11-12 2011-05-12 Genentech, Inc. Method of promoting dendritic spine density
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
PL3042917T3 (pl) * 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
US20150209367A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye & Ear Infirmary Treating Hearing Loss
CN120904322A (zh) 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
JP6840774B2 (ja) 2016-05-16 2021-03-10 ザ ジェネラル ホスピタル コーポレイション 肺上皮エンジニアリングにおけるヒト気道幹細胞
US20210355138A1 (en) * 2016-08-11 2021-11-18 Eli Lilly And Company Aminothiazinies and their use as bace1 inhibitors
CN118370815A (zh) 2017-08-22 2024-07-23 渤健马萨诸塞州股份有限公司 含有抗β淀粉样蛋白抗体的药物组合物
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CA3243602A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062801A2 (en) * 2000-02-24 2001-08-30 Washington University Humanized antibodies that sequester amyloid beta peptide
WO2002046237A2 (en) * 2000-12-06 2002-06-13 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
WO2002088306A2 (en) * 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001232A3 (en) 1996-12-23 2001-02-28 Elan Pharmaceuticals Inc San F Cycloalkyl, lactam, lactone derivatives and their thio analogues inhibiting betha-amyloid peptide release and/or its synthesis and pharmaceutical compositions containing the compounds
US6518011B1 (en) * 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
JP2003530437A (ja) * 2000-04-13 2003-10-14 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ Ａβ４２低下物質

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062801A2 (en) * 2000-02-24 2001-08-30 Washington University Humanized antibodies that sequester amyloid beta peptide
WO2002046237A2 (en) * 2000-12-06 2002-06-13 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
WO2002088306A2 (en) * 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies

Also Published As

Publication number Publication date
CN1922209B (zh) 2012-09-05
AU2005217596A1 (en) 2005-09-09
CA2556436A1 (en) 2005-09-09
KR20060126785A (ko) 2006-12-08
PT1720909E (pt) 2011-12-23
US20070190046A1 (en) 2007-08-16
DK1720909T3 (da) 2012-01-30
JP2008500279A (ja) 2008-01-10
JP4851348B2 (ja) 2012-01-11
CY1112162T1 (el) 2015-12-09
EP1720909A2 (en) 2006-11-15
WO2005082939A2 (en) 2005-09-09
EA200601545A1 (ru) 2007-02-27
WO2005082939A3 (en) 2005-10-27
KR20090005410A (ko) 2009-01-13
IL177611A (en) 2013-05-30
EA009872B1 (ru) 2008-04-28
CA2556436C (en) 2014-04-01
EP1720909B1 (en) 2011-11-23
KR100889430B1 (ko) 2009-03-23
ES2375627T3 (es) 2012-03-02
PL1720909T3 (pl) 2012-04-30
SI1720909T1 (sl) 2012-01-31
NO20064239L (no) 2006-11-20
UA93181C2 (ru) 2011-01-25
ATE534667T1 (de) 2011-12-15
CN1922209A (zh) 2007-02-28
IL177611A0 (en) 2006-12-10
BRPI0507856A (pt) 2007-07-10

Similar Documents

Publication Publication Date Title
AU2005217596B2 (en) Anti-ABeta antibody
US11078261B2 (en) Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
TWI747922B (zh) 特異性針對過度磷酸化τ蛋白之抗體及其使用方法
JP6462750B2 (ja) 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
CN109937210B (zh) 用于治疗共核蛋白病的药剂、用途和方法
RU2760334C2 (ru) Моноклональные антитела к альфа-синуклеину для предотвращения агрегации тау-белка
JP2003523764A (ja) Ａβペプチドを隔離するヒト化抗体
KR20090019911A (ko) 아밀로이드 β(1-42) 올리고머, 이의 유도체, 이에 대한 항체, 이의 제조 방법 및 용도
TW201739761A (zh) 抗－N3pGlu 類澱粉β肽抗體及其用途
EA012162B1 (ru) Способ рефолдинга рекомбинантных антител
JP2017509594A (ja) マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
JP7221352B2 (ja) 抗ｐａｃａｐ抗体
WO2025180021A1 (zh) 一种抗人与鼠TfR的抗体或其抗原结合片段及其用途
WO2022156799A1 (zh) 一种抗体及其用途
KR20230093499A (ko) 인간 대상체에서 타우를 감소시키는 방법
CN114213541B (zh) 一种全能核酸酶的单克隆抗体及其制备方法
MXPA06009560A (en) Anti-abeta antibody
EA041243B1 (ru) Антитела к бета-амилоидному пептиду n3pglu и их применение

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired